Cure My Disease

Don't miss your cure!

 Log in / Sign up

Zapping nerves with radiation may ease pancreatic cancer pain

NCT ID NCT07689955

Symptom relief Sponsor: Royal Marsden NHS Foundation Trust Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 08, 2026 · Last updated Jul 09, 2026 · Updated 1 time

Summary

This trial tests whether a short course of precisely targeted radiotherapy can safely reduce severe pain in people with advanced pancreatic cancer. The radiation is aimed at the coeliac plexus, a network of nerves in the abdomen that often causes pain when affected by the tumor. Participants receive Intensity Modulated Radiotherapy (IMRT), a technique that shapes radiation beams to spare healthy tissue. The main goal is to see if pain scores drop by at least 30% without increasing painkiller use. If successful, this approach could offer a non-invasive, widely available pain relief option across the UK.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Intensity Modulated Radiotherapy (IMRT) to the coeliac plexus
What this could lead to
If it works, this could offer a non-invasive, widely available option to ease severe pain in advanced pancreatic cancer, reducing reliance on strong painkillers.
What could go wrong
This is a small, early-phase trial with no control group, so results may not be definitive. Radiotherapy to the abdomen can cause side effects like nausea or fatigue, and pain relief may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 52 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Sep 2031

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Pain with a BPI score ≥ 2 as a result of pancreatic adenocarcinoma, not sufficiently responding to opiate medication. 2. Primarily unresectable or locally advanced pancreatic adenocarcinoma with or without metastases. 3. Participant is not considered suitable for a potentially radical treatment pathway (including radical chemoradiotherapy, SABR, or surgery with curative intent). 4. Histological or cytological confirmation of adenocarcinoma of the pancreas. 5. Diagnostic CT scan not older than 2 months before study entry. 6. Age ≥ 18 years. 7. If the participant is receiving systemic anti-cancer therapy (SACT), the following minimum washout periods must be achievable: 1. A minimum interval of 7 days between the last dose of SACT and the start of radiotherapy. 2. A minimum interval of 7 days between completion of radiotherapy and recommencement of SACT. 8. Able to provide informed consent and has provided written, signed, and dated consent. 9. The ability to answer questionnaires. Exclusion Criteria: 1. Resectable or borderline resectable tumours without distant metastases. 2. Locally advanced pancreatic adenocarcinoma without distant metastases where a higher dose of radiation delivery for local control is deemed in the participant's best interests. 3. Participants who are unable to have a washout window from their SACT are ineligible for the trial. 4. Pregnant women. 5. Predicted prognosis less than 8 weeks. 6. Prior radiotherapy to the abdomen.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Pancreatic adenocarcinoma are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

malignant pancreatic neoplasm pancreatic adenocarcinoma pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pancreatic cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.